chr11-71444125-C-T

Variant summary

Our verdict is Benign. The variant received -19 ACMG points: 0P and 19B. BP4_ModerateBP6_Very_StrongBP7BA1

The NM_001360.3(DHCR7):​c.189G>A​(p.Gln63Gln) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.678 in 1,610,010 control chromosomes in the GnomAD database, including 392,378 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.58 ( 27496 hom., cov: 33)
Exomes 𝑓: 0.69 ( 364882 hom. )

Consequence

DHCR7
NM_001360.3 synonymous

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:13

Conservation

PhyloP100: 3.07

Publications

29 publications found
Variant links:
Genes affected
DHCR7 (HGNC:2860): (7-dehydrocholesterol reductase) This gene encodes an enzyme that removes the C(7-8) double bond in the B ring of sterols and catalyzes the conversion of 7-dehydrocholesterol to cholesterol. This gene is ubiquitously expressed and its transmembrane protein localizes to the endoplasmic reticulum membrane and nuclear outer membrane. Mutations in this gene cause Smith-Lemli-Opitz syndrome (SLOS); a syndrome that is metabolically characterized by reduced serum cholesterol levels and elevated serum 7-dehydrocholesterol levels and phenotypically characterized by cognitive disability, facial dysmorphism, syndactyly of second and third toes, and holoprosencephaly in severe cases to minimal physical abnormalities and near-normal intelligence in mild cases. Alternative splicing results in multiple transcript variants that encode the same protein.[provided by RefSeq, Aug 2009]
DHCR7 Gene-Disease associations (from GenCC):
  • Smith-Lemli-Opitz syndrome
    Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, G2P, Myriad Women’s Health, Laboratory for Molecular Medicine, ClinGen, Labcorp Genetics (formerly Invitae)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -19 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.44).
BP6
Variant 11-71444125-C-T is Benign according to our data. Variant chr11-71444125-C-T is described in ClinVar as Benign. ClinVar VariationId is 93713.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=3.07 with no splicing effect.
BA1
GnomAd4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.73 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
DHCR7NM_001360.3 linkc.189G>A p.Gln63Gln synonymous_variant Exon 4 of 9 ENST00000355527.8 NP_001351.2 Q9UBM7A0A024R5F7

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
DHCR7ENST00000355527.8 linkc.189G>A p.Gln63Gln synonymous_variant Exon 4 of 9 1 NM_001360.3 ENSP00000347717.4 Q9UBM7
DHCR7ENST00000685320.1 linkc.-333-64G>A intron_variant Intron 2 of 7 ENSP00000509319.1 B4E1K5

Frequencies

GnomAD3 genomes
AF:
0.578
AC:
87821
AN:
151986
Hom.:
27466
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.403
Gnomad AMI
AF:
0.674
Gnomad AMR
AF:
0.536
Gnomad ASJ
AF:
0.616
Gnomad EAS
AF:
0.365
Gnomad SAS
AF:
0.201
Gnomad FIN
AF:
0.569
Gnomad MID
AF:
0.458
Gnomad NFE
AF:
0.736
Gnomad OTH
AF:
0.554
GnomAD2 exomes
AF:
0.565
AC:
137936
AN:
243970
AF XY:
0.558
show subpopulations
Gnomad AFR exome
AF:
0.395
Gnomad AMR exome
AF:
0.539
Gnomad ASJ exome
AF:
0.625
Gnomad EAS exome
AF:
0.372
Gnomad FIN exome
AF:
0.580
Gnomad NFE exome
AF:
0.716
Gnomad OTH exome
AF:
0.601
GnomAD4 exome
AF:
0.688
AC:
1002927
AN:
1457908
Hom.:
364882
Cov.:
53
AF XY:
0.674
AC XY:
488636
AN XY:
724926
show subpopulations
African (AFR)
AF:
0.373
AC:
12489
AN:
33438
American (AMR)
AF:
0.539
AC:
23709
AN:
43964
Ashkenazi Jewish (ASJ)
AF:
0.626
AC:
16335
AN:
26076
East Asian (EAS)
AF:
0.333
AC:
13174
AN:
39572
South Asian (SAS)
AF:
0.215
AC:
18444
AN:
85718
European-Finnish (FIN)
AF:
0.587
AC:
31052
AN:
52894
Middle Eastern (MID)
AF:
0.466
AC:
2684
AN:
5764
European-Non Finnish (NFE)
AF:
0.763
AC:
846811
AN:
1110252
Other (OTH)
AF:
0.635
AC:
38229
AN:
60230
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.475
Heterozygous variant carriers
0
14876
29753
44629
59506
74382
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
20052
40104
60156
80208
100260
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.578
AC:
87896
AN:
152102
Hom.:
27496
Cov.:
33
AF XY:
0.562
AC XY:
41785
AN XY:
74340
show subpopulations
African (AFR)
AF:
0.404
AC:
16751
AN:
41472
American (AMR)
AF:
0.536
AC:
8199
AN:
15290
Ashkenazi Jewish (ASJ)
AF:
0.616
AC:
2137
AN:
3468
East Asian (EAS)
AF:
0.365
AC:
1893
AN:
5182
South Asian (SAS)
AF:
0.203
AC:
977
AN:
4814
European-Finnish (FIN)
AF:
0.569
AC:
6027
AN:
10590
Middle Eastern (MID)
AF:
0.476
AC:
138
AN:
290
European-Non Finnish (NFE)
AF:
0.736
AC:
50006
AN:
67978
Other (OTH)
AF:
0.548
AC:
1156
AN:
2110
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.500
Heterozygous variant carriers
0
1743
3486
5229
6972
8715
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
714
1428
2142
2856
3570
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.665
Hom.:
19070
Bravo
AF:
0.578
Asia WGS
AF:
0.265
AC:
925
AN:
3478

ClinVar

Significance: Benign
Submissions summary: Benign:13
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Smith-Lemli-Opitz syndrome Benign:6
Oct 05, 2021
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jul 01, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Aug 09, 2017
Natera, Inc.
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Jan 12, 2018
Illumina Laboratory Services, Illumina
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -

Feb 04, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

May 08, 2017
Athena Diagnostics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not specified Benign:4
-
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jun 06, 2018
Eurofins Ntd Llc (ga)
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

-
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

not provided Benign:2
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Mar 03, 2015
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Inborn genetic diseases Benign:1
Mar 11, 2016
Ambry Genetics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.44
CADD
Benign
13
DANN
Benign
0.84
PhyloP100
3.1
Mutation Taster
=90/10
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.19
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs1044482; hg19: chr11-71155171; COSMIC: COSV62794719; COSMIC: COSV62794719; API